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INTRODUCTION 
 
GLOBAL TRENDS IN CARDIOVASCULAR DISEASE  
Estimating global trends in the burden of disease, particularly CVD, 
is aided by examining regional trends. Because 85 percent of the world's 
population lives in the low- and middle-income countries, global rates of 
CVD are largely driven by rates in these countries. Even as rates fall in 
high-income countries, worldwide CVD rates are accelerating because 
most low- and middle-income countries are entering the second and third 
phases of the epidemic transition, marked by rising CVD rates. 
The economic impact of chronic diseases could be substantial as this 
transition proceeds. Over the next decade or so, countries such as China, 
India, and Russia could forego between $200 billion and $550 billion in 
national income as a result of heart disease, stroke, and diabetes. 
In 1990 CVD accounted for 28 percent of the world's 50.4 million 
deaths and 9.7 percent of the 1.4 billion lost DALYs. By 2001, CVD was 
responsible for 29 percent of all deaths and 14 percent of the 1.5 billion 
lost DALYs. 
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By 2020, the population will grow to 7.8 billion and 32 percent of 
all deaths will be due to CVD, and by 2030, when the population is 
expected to reach 8.2 billion, 33 percent of all deaths will be caused by 
CVD.   By 2030, the WHO predicts that worldwide CVD will cause 24.2 
million deaths.   Of these, 14.9 percent of deaths in men and 13.1 percent 
of deaths in women will be due to CHD. Stroke will be responsible for 
10.4 percent of all male deaths and 11.8 percent of all female deaths.  
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TABLE  
Contribution of Various Disease Categories to Global Mortality 
      Total Deaths (%) 
  Population 
(Millions) 
Total 
Deaths 
(Millions)
CMPN Injury Non-
CMPN 
Non-
CVD 
All 
CVD 
CHD Stroke
1990 
World 5267 50.4 34.2 10.1 27.4 28.4 12.4 8.7 
High 
income 
798 7.12 6.4 6.2 42.8 44.6 23.4 11.1 
Low 
and 
middle 
income 
4470 43.3 38.7 10.7 24.8 25.7 10.6 8.3 
2001 
World 6148 56.2 32.3 9.2 29.3 29.1 12.5 9.6 
High 
income 
929 7.9 7.0 6.0 48.5 38.5 17.3 9.9 
Low 
and 
middle 
income 
5219 48.3 36.4 9.7 26.2 27.6 11.8 9.5 
2020[*] 
World 7800 65.1       31.5 13.6 10.6 
2030[*] 
World 8200 74.5       32.5 14.0 11.1 
CHD = coronary heart disease; CMPN = communicable diseases, maternal 
and perinatal conditions, and nutritional deficiency; CVD = cardiovascular 
disease. 
* Modified from Mackay J, Mensah G: Atlas of Heart Disease and Stroke. 
Geneva, World Health Organization, 2004. 
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HIGH-INCOME COUNTRIES  
In the high-income countries, population growth will be fueled by 
emigration from the low- and middle-income countries, but as a proportion 
of the world's population, the high-income segment is gradually shrinking. 
In the high-income countries, the modest decline in CVD death rates begun 
in the latter third of the 20th century will continue, but the rate of decline 
appears to be slowing. However, these countries are expected to see an 
increase in the prevalence of CVD, as well as the absolute number of 
deaths, predicted to increase between 30 percent and 60 percent, as 
populations age. 
LOW- AND MIDDLE-INCOME COUNTRIES 
Of the 7.1 million individuals who died from ischemic heart disease 
in 2001, 5.7 million lived in low- and middle-income countries.  And of 
the 5.4 million people who died from a stroke in 2001, less than 1 million 
lived in high-income countries. From 1990 to 2001, the percentage of 
deaths from communicable diseases decreased from 38.7 percent to 36.4 
percent and continued substantial declines are expected.  Although some 
countries are still in the first and second phases of the epidemiological 
transition, large portions of the population living in low- and middle-
12 
 
income countries have entered the third phase and some are entering the 
fourth.   
Today, in most of the regions, the pattern is typical, with CHD rates 
exceeding stroke rates. Exceptions include sub-Saharan Africa and China, 
home to the vast majority of East Asia and Pacific residents. In sub-
Saharan Africa, which is in an earlier stage of the transition, this ratio is 
currently about 1:1, but the balance is likely to shift in favor of CHD over 
time.  
In China, however, the ratio is reversed, with stroke rates exceeding 
CHD rates, but this is also likely to change. In urban China, CHD rates are 
rapidly increasing as stroke rates fall. Changing demographics play a 
significant role in future predictions for CVD throughout the world. For 
example, between 1990 and 2001, the population of Europe and Central 
Asia grew by 1 million people per year, whereas South Asia added 25 
million people each year 
In their report A Race Against Time: The Challenge of 
Cardiovascular Disease in Developing Economies, Leeder and colleagues 
compare the role of CVD in the death patterns of one low-income country 
(India) and four middle-income countries (Russia, Brazil, China, and South 
Africa) in 2000 and in the future. Portugal and the United States were used 
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as high-income comparator countries. Even assuming no increase in CVD 
risk factors, the authors predict that all five study countries, but especially 
India and South Africa, will see a dramatic number of working-age people 
(35 to 64 years old) die of CVD over the next 30 years, as well as an 
increasing level of morbidity among middle-aged people related to heart 
disease and stroke. In China, they estimate that there will be 9 million 
deaths from CVD in 2030—up from 2.4 million in 2002—with half 
occurring in individuals between 35 and 64 years old. 
Because of a growing population of younger people at risk for CVD 
in the five study countries, they predict that the proportion of CVD deaths 
occurring in the prime labor years will greatly exceed the experience of the 
United States and Portugal. Predictions of the increase in the number of 
productive years lost due to CVD between 2000 and 2030 are: South 
Africa, 28 percent; China, 57 percent; Brazil, 64 percent; and India, 95 
percent. (In South Africa and Brazil, the predicted rates per 100,000 
population actually decrease slightly as a result of anticipated demographic 
changes.) 
In Russia, the number is predicted to decrease because the size of 
the population at risk is falling. For comparison, the number of years of 
productive life lost is expected to increase by 20 percent in the United 
States and by 30 percent in Portugal by 2030.  
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The ultimate promise of an improved understanding of 
cardiovascular risk is the concept of “personalized medicine,” in which 
targeted interventions can get the right drug to the right patient at the right 
time.  
By the mid-1960s, investigators in the Framingham Heart Study had 
defined the major risk factors of age, hypertension, smoking, and 
hyperlipidemia, and coined the term coronary risk factors. Over time, 
these four biomarkers, along with gender, have generated global risk 
prediction scores for the assessment of cardiovascular risk.  However, as 
also described earlier, one vascular event in five occurs in the absence of 
any of these major risk factors and one in two in the absence of 
hyperlipidemia.  From a research perspective, the past 50 years has seen a 
remarkable expansion in our understanding of atherothrombosis to include 
the biology of hemostasis, thrombosis, inflammation, and endothelial 
dysfunction.  Despite this changing view of pathophysiology, the variables 
in current risk assessment algorithms remain largely unchanged from those 
evaluated a half-century ago. 
 
 
15 
 
An expanded and updated approach to vascular risk detection is 
needed so that primary care physicians can be guided by the most modern 
biological constructs. New risk prediction algorithms must involve 
rigorous evaluation, with particular care given not only to the concepts of 
discrimination but also calibration and reclassification. This change in 
focus for prevention must include an understanding that reliance on the    
C-statistic as a traditional method for selecting variables for inclusion in 
risk prediction models is outmoded and subject to considerable error.   
Indeed, careful investigation has shown that inappropriate reliance on the 
C-statistic would actually eliminate LDL cholesterol, HDL cholesterol, and 
blood pressure from most global prediction models. Furthermore, 
continued reliance on 10-year risk estimates rather than estimates of 
lifetime risk may actually restrain more effective prevention efforts. 
In an effort to move beyond traditional risk variables, a few recent 
investigations have ascertained wide panels of biomarkers in large cohorts 
of initially healthy individuals who were then followed prospectively for 
incident vascular events. For example, using such data in the Women's 
Health Study, nine variables—age, current smoking, systolic blood 
pressure, hemoglobin A1c among diabetics, hsCRP, apo B-100, apo A-I, 
Lp(a), and a parental history of premature atherosclerosis—were found to 
improve risk prediction substantially when compared with traditional 
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Framingham covariates. Importantly, use of this novel algorithm 
reclassified nearly 50 percent of those otherwise considered to be at 
intermediate risk on the basis of usual risk factors, an effect that was also 
seen for a simplified prediction model that substituted non-HDL 
cholesterol for apo B-100 and HDL cholesterol for apo A-I. Moreover, this 
reclassification was correct in over 90 percent of cases 
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AIMS AND OBJECTIVES 
 
 
1. To determine the PREVALANCE OF ELEVATED HsCRP IN 
50 PATIENTS WITH ACUTE VASCULAR EVENTS  
2. To compare with 50 controls of non vascular acute event. 
3. To determine role of HsCRP in determining the morbidity and 
mortality.  
4. To study the prognostic implication of HsCRP in acute vascular 
events. 
5. To analyse the levels in patient with out any other specific CVS 
risk factors. 
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REVIEW OF LITERATURE 
 
ATHEROSCLEROTIC RISK FACTORS  
Despite the importance of blood lipids, 50 percent of all myocardial 
infarctions and stroke occur in individuals without overt hyperlipidemia.  
In a major prospective study of healthy American women, 77 percent of all 
future cardiovascular events occurred in patients with LDL cholesterol 
levels less than 160 mg/dl and 46 percent occurred in those with LDL 
cholesterol levels less than 130 mg/dl.[1]  
Although the use of global prediction models like those developed in 
Framingham greatly improves the detection of heart disease risk, as many 
as 20 percent of all events occur in the absence of any of the major classic 
vascular risk factors.  This fact challenges several basic issues related to 
current screening programs for risk detection and disease prevention. 
However, clinical data continue to accurate demonstrating the hazard of 
relying solely on classic risk factors. 
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 In one analysis more than 120,000 patients with coronary heart 
disease, 15 percent of the women and 19 percent of the men had no 
evidence of hyperlipidemia, hypertension, diabetes, or smoking and more 
than 50 percent had only one of these general risk factors.[2]  
In another large analysis, between 85 and 95 percent of participants 
with coronary disease had at least one conventional risk factor, but so too 
did those participants without coronary disease despite follow-up for as 
long as 30 years[3].  Thus, because of the considerable need to improve 
vascular risk detection, much research over the past 10 or 15 years has 
focused on the identification and evaluation of novel atherosclerotic risk 
factors[4].   
When evaluating any novel risk factor as a potential new screening 
tool, clinicians need to consider whether:  
1. There is a standardized and reproducible assay for the marker of interest. 
2. There is a consistent series of prospective studies demonstrating that a 
given parameter predicts future risk. 
3. The novel marker adds to the predictive value of lipid screening.   
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4. There is evidence that the novel marker adds to global risk prediction 
scores, such as that in the Framingham Heart Study.  The following 
section applies these basic epidemiological requirements to a series of 
novel risk factors, including hsCRP and other markers of inflammation, 
lipoprotein(a), homocysteine, and markers of fibrinolytic and 
hemostatic function, such as fibrinogen, D-dimer, tissue plasminogen 
activator (t-PA), and plasminogen activator inhibitor 1 (PAI-1) 
antigens.  Shows data describing the relative efficacy of several 
variables measured at baseline in two large cohorts of initially healthy 
middle-aged men and women.  
TABLE 1 
Clinical Epidemiology of Proposed Plasma-Based Biomarkers for 
Prediction of Future Cardiovascular Events 
 
Biomarker 
Prospective 
Studies 
Convincing?
Standardized 
Commercial 
Assay? 
Additive to 
Lipid 
Screening?
Additive to 
Framingham 
Risk Score? 
Inflammation 
  hsCRP ++++ +++ +++ +++ 
  sICAM-1 ++ ± + - 
  SAA ++ - + - 
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Biomarker 
Prospective 
Studies 
Convincing?
Standardized 
Commercial 
Assay? 
Additive to 
Lipid 
Screening?
Additive to 
Framingham 
Risk Score? 
  IL-6/IL-18 ++ - + - 
  Myeloperoxidase + - ± - 
  sCD40L + - - - 
Altered thrombosis 
  t-PA/PAI-1 ++ ± - - 
  Fibrinogen +++ ± ++ - 
  Homocysteine ++++ +++ ± - 
  D-dimer ++ + - - 
Oxidative stress-
oxidized LDL 
± - - - 
Altered lipids 
 Lipoprotein(a) +++ ± ± - 
 LDL particle size ++ ± ± - 
 
 
 (9SS(( 
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High-Sensitivity C-Reactive Protein 
Inflammation characterizes all phases of atherothrombosis and 
provides a critical pathophysiological link between plaque formation and 
acute rupture, leading to occlusion and infarction[5].  Formation of the fatty 
streak, the earliest phase of atherogenesis, involves recruitment of 
leukocytes caused by the expression of adhesion molecules on endothelial 
cells, in turn triggered by inflammatory cytokines such as interleukin-1 and 
tumor necrosis factor-alpha. Subsequent migration of inflammatory cells 
into the subendothelial space requires chemotaxis controlled by 
chemokines induced by the primary cytokines.  Mononuclear cells within 
this initial infiltrate, as well as intrinsic vascular cells, subsequently release 
growth factors that stimulate proliferation of the smooth muscle cells and 
lead to plaque progression. The thrombotic complications of plaques often 
involve physical disruption, usually associated with signs of local and 
systemic inflammation.  
Other proinflammatory cytokines such as CD40 ligand can in turn 
induce tissue factor expression and promote thrombus formation. 
Moreover, the primary proinflammatory cytokines result in the expression 
of messenger cytokines such as interleukin-6, which can travel from local 
sites of inflammation to the liver, where a change in the program of protein 
synthesis characteristic of the acute phase response is thereby triggered. 
25 
 
The acute-phase reactant, CRP, a simple downstream marker of 
inflammation, has now emerged as a major cardiovascular risk factor.[6] 
Composed of five 23-kDa subunits, CRP is a circulating member of 
the pentraxin family that plays a major role in the human innate immune 
response. Although derived primarily from the liver, studies have found 
that cells within human coronary arteries, particularly in the atherosclerotic 
intima, can also elaborate CRP.  
More than simply a marker of inflammation, CRP may influence 
directly vascular vulnerability through several mechanisms, including 
enhanced expression of local adhesion molecules, increased expression of 
endothelial PAI-1, reduced endothelial nitric oxide bioactivity, altered 
LDL uptake by macrophages, and colocalization with complement within 
atherosclerotic lesions. Moreover, expression of human CRP in CRP-
transgenic mice was found to directly enhance intravascular thrombosis.[7]  
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The evidence for direct proinflammatory effects of CRP has less 
strength at present than the consistent data regarding its ability to predict 
risk.  In primary prevention, a large series of prospective epidemiological 
studies has demonstrated convincingly that CRP, when measured with 
high-sensitivity assays, strongly and independently predicts risk of 
myocardial infarction, stroke, peripheral arterial disease, and sudden 
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cardiac death among apparently healthy individuals. These data apply to 
women as well as men across all age levels and have been consistent in 
diverse populations. Most importantly, hsCRP adds prognostic information 
at all levels of LDL cholesterol and at all levels of risk, as determined by 
the Framingham Risk Score. [8]  
In other major studies from the United States and Europe, hsCRP 
levels predicted subsequent risk better than LDL cholesterol level. [9] [10] 
However, because hsCRP levels reflect a component of vascular risk 
different from that of cholesterol, the addition of hsCRP to lipid evaluation 
provides a major opportunity to improve global risk prediction.  
In clinical terms, absolute vascular risk is higher in individuals with 
elevated hsCRP levels and low levels of LDL cholesterol than in those 
with elevated levels of LDL cholesterol but low levels of hsCRP, but 
current guidelines consider only the latter group to be at high risk Even in 
studies that have reported the effect of hsCRP as modest, the magnitude of 
effect was at least as large as that of hypertension and smoking, data 
demonstrating the importance of inflammation in atherogenesis.[11]  
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Largely on the basis of these data, the American Heart Association 
and the Centers for Disease Control and Prevention issued guidelines in 
2003 for the use of hsCRP in clinical practice.[11] 
 Briefly,  
HsCRP levels  <1mg/dl LOW RISK 
       1 to 3mg/dl INTERMEDIATE  
    > 3 mg/liter  HIGHER relative vascular risk  
respectively, when considered along with traditional markers of risk. This 
critical finding has corroborated studies conducted worldwide; all studies 
of adequate sample size have found the risk of hsCRP to be independent of 
and additive to traditional risk factors [12] [8] [13] [14] [15] [16] [17].  Screening for 
hsCRP should be done at the discretion of the physician as part of global 
risk evaluation, not as a replacement for LDL and HDL testing.  
Although hsCRP predicts risk across the entire population spectrum, 
its greatest usefulness is likely to be for those at intermediate risk—that is, 
individuals with anticipated 10-year event rates between 5 and 20 percent. 
In a recent analysis of the impact that CRP makes on clinical risk 
prediction, global risk prediction models that included hsCRP reclassified 
approximately 20 percent of those otherwise considered to be at 
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intermediate risk; moreover, the impact of hsCRP on risk prediction was at 
least as large as that of lipid screening.[18]  
Values of hsCRP in excess of 8 mg/liter may represent an acute-
phase response caused by an underlying inflammatory disease or 
intercurrent infection and should lead to repeat testing in approximately 2 
to 3 weeks; consistently high values, however, represent very high risk of 
future cardiovascular disease, because risk appears to be linear across the 
full range of hsCRP levels.[19] Because hsCRP levels are stable over long 
periods, have no circadian variation, and do not depend on prandial state, 
screening can easily be done on an outpatient basis at the time of 
cholesterol evaluation.  
All these data support the concept that inflammation plays a critical 
role throughout the atherothrombotic process. Additionally, hsCRP has 
prognostic usefulness in cases of acute ischemia, even without troponin 
level elevation, suggesting that an enhanced inflammatory response at the 
time of hospital admission can determine subsequent plaque rupture.[20] 
These findings help explain why individuals with elevated hsCRP levels 
are also more likely to benefit from aggressive interventions compared 
with those with low hsCRP levels.  
Elevated levels of hsCRP predict not only cardiovascular events but 
also the onset of type 2 diabetes mellitus, [21] [22] perhaps because hsCRP 
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levels correlate with several components of the metabolic syndrome, 
including those not easily measured in clinical practice such as insulin 
sensitivity, endothelial dysfunction, and hypofibrinolysis. Thus, hsCRP 
assessment also adds prognostic information at all levels of the metabolic 
syndrome. [23] [24] 
In the AFCAPS/TexCAPS trial, for example, statin appeared to 
lower cardiovascular event rates, even for those with below-median levels 
of LDL cholesterol but above-median levels of hsCRP.[25]   
In the PROVE IT-TIMI 22 clinical trial conducted in patients with 
acute coronary syndromes treated with statin therapy, achieving levels of 
hsCRP less than 2 mg/liter was as important for long-term event-free 
survival as was achieving levels of LDL cholesterol less than 70 mg/dl; in 
fact, the best long-term outcomes were found in those who achieved both 
these goals [26].  This new concept of “dual goals” for statin therapy, which 
includes both CRP andLDL level reduction, has been corroborated in the 
A-to-Z clinical trial,[27] 
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According to AFCAPS trial 
 
 
 
Although hsCRP is by far the best-characterized and most reliable 
inflammatory biomarker for clinical use, several other markers of 
inflammation have shown promise in terms of predicting vascular risk. 
These include cytokines such as interleukin-6, soluble forms of certain cell 
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adhesion molecules such as intercellular adhesion molecule (sICAM-1),  
P-selectin, or the mediator CD40 ligand, as well as markers of leukocyte 
activation such as myeloperoxidase. 
Other inflammatory markers associated with lipid oxidation such as 
lipoprotein-associated phospholipase A2 and pregnancy-associated plasma 
protein A have also shown promise. However, each of these biomarkers 
has analytical issues that need careful evaluation before routine clinical 
use. 
For example, some have too short a half-life for clinical diagnostic 
testing, whereas the ability of others to predict risk in settings of broad 
populations has proved marginal thus far. Nonetheless, several of these 
inflammatory biomarkers can shed critical pathophysiological light on the 
atherothrombotic process, particularly at the time of plaque rupture. For 
example, soluble CD40 ligand (probably released from activated platelets) 
may provide insight into the efficacy of specific antithrombotic agents 
independently of CRP. 
Similarly, myeloperoxidase may provide prognostic information in 
cases of acute ischemia over and above that associated with troponin or 
CRP.Thus, continued evaluation of other inflammatory biomarkers may 
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well provide targets for or monitors of therapy, particularly in the setting 
of acute coronary ischemia. 
 
 
Homocysteine  
Homocysteine is a sulfhydryl-containing amino acid derived from 
the demethylation of dietary methionine.  Patients with rare inherited 
defects of methionine metabolism can develop severe 
hyperhomocysteinemia (plasma levels higher than 100µmol/liter) and have 
markedly elevated risk of premature atherothrombosis as well as venous 
thromboembolism. Mechanisms suggested to account for these effects 
include endothelial dysfunction, accelerated oxidation of LDL cholesterol, 
impairment of flow-mediated endothelium-derived relaxing factor with 
subsequent reduction in arterial vasodilation, platelet activation, and 
oxidative stress.  
In contrast to severe hyperhomocysteinemia, mild to moderate 
elevations of homocysteine (plasma levels higher than 15µmol/liter) are 
more common in the general population, primarily because of insufficient 
dietary intake of folic acid. Other patient groups who tend to have elevated 
levels of homocysteine include those receiving folate antagonists such as 
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methotrexate and carbamazepine and those with impaired homocysteine 
metabolism caused by hypothyroidism or renal insufficiency. 
 
 
Despite reduced enthusiasm and lack of evidence that homocysteine 
reduction lowers risk, there remain a few specific patient populations for 
whom homocysteine evaluation may prove appropriate, including those 
lacking traditional risk factors, with renal failure, or with markedly 
premature atherosclerosis or a family history of myocardial infarction and 
stroke at a young age. It is also crucial to continue folate supplementation 
in the general population to reduce the risk of neural tube defects, an 
inexpensive practice that has been in place in the United States for over a 
decade yet remains a public health challenge for much of Europe and the 
developing world 
Fibrinogen and Fibrin D-Dimer  
Plasma fibrinogen influences platelet aggregation and blood 
viscosity, interacts with plasminogen binding and, in combination with 
thrombin, mediates the final step in clot formation and the response to 
vascular injury. In addition, fibrinogen associates positively with age, 
obesity, smoking, diabetes, and LDL cholesterol level, and inversely with 
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HDL cholesterol level, alcohol use, physical activity, and exercise level. 
Fibrinogen, like CRP, is an acute-phase reactant and increases during 
inflammatory responses. 
 
Given these relationships, it is not surprising that fibrinogen was 
among the first “novel” risk factors evaluated. Early reports from the 
Gothenburg, Northwick Park, and Framingham heart studies all found 
significant positive associations between fibrinogen levels and future risk 
of cardiovascular events. Since then, a number of other prospective studies 
have confirmed these findings and, in recent meta-analyses, there was an 
approximately linear logarithmic association between usual fibrinogen 
level and the risk of coronary heart disease and stroke. In one analysis, the 
age- and gender-adjusted hazard ratio per 1-g/liter increase in fibrinogen 
was 2.4 for coronary heart disease and 2.1 for stroke. 
Interestingly, these effects were largely unaffected in those studies 
in which further adjustment for hsCRP was possible. In more recent 
studies, hsCRP and fibrinogen levels appeared to be additive in their 
ability to predict risk, although the absolute effect of hsCRP appeared to be 
larger.  Other studies have suggested that the predictive usefulness of 
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fibrinogen is highest in those with other concomitant elevations of 
lipoprotein(a) or homocysteine. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                           
MATERIALS AND METHODS 
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MATERIAL AND METHODS 
STUDY POPULATION  
 A total of 50 patients were enrolled for the study from who attended 
the in patient clinics of the institute of Internal Medicine and department of 
cardiology.  
 Patients are selected for the study who satisfied all the inclusion and 
exclusion criteria. Written consent was obtained from all patients 
participating in the study. 
 Age and sex matched controls (50) were also studied for comparison 
and meaningful interpretation of data. The controls were recruited from 
other acute cases that were recruited from the wards; appropriate controls 
38 
 
were recruited from the wards. All patients and controls were not from a 
single ethnic background.  
STUDY DURATION 
This study was conducted for a period of eighteen months from 
January 2008 to September 2009. 
 
 
STUDY DESIGN  
 A single centre matched care- control study design was chosen.  
METHODS  
 Detailed clinical history were taken from each patients and a 
completes review of their case notes performed. A complete clinical 
examination of the nervous system and cardiovascular system was done for 
each patient.  
LABORATORY METHODS  
 To all selected patients, following investigations were taken. 
¾ ECG  
¾ ECHO 
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¾ CPK MB  
¾ CT BRAIN  
¾ FBS 
¾ FLP  
¾ HsCRP 
¾ Other relevant investigations 
 
 
INCLUSION CRITERIA 
FOR CASES 
          1. Age more than 12 years. 
          2. Acute myocardial infarction  
  Evidenced by ECG, elevated CK MB, or ECHO      
3. Ischemic stroke 
Two CT BRAIN taken at least 3 days gap showing signs of  
ischemia  
 4. Unstable angina  
  Evidenced by ECG or elevated CK MB 
 5. Those who are willing for study 
FOR CONTROL 
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1. Age more than 15 less than 60. 
2. Presence of any illness 
3. Event should be acute 
4. No cardiovascular  risk factors 
 
 
 
EXCLUSION CRITERIA 
1. Age less than 15 and more than 60 
2. Smoking 
3. Alcoholism 
4. Patient with previous attacks 
5. Other inflammatory conditions 
a. SLE 
b. Scleroderma 
c. Rheumatoid arthritis 
d. Other Connective Tissue Disorders 
6. Immunosuppresant therapy 
7. Patient lost followup 
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STATISTICAL ANALYSIS 
The significance of difference between two proportions was 
indicated by the chi-square (x2) statistic. The significance of difference in 
mean between two groups was calculated by student t-test. Variables were 
considered to be significant if (P<0.05).  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
OBSERVATION AND RESULTS 
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OBSERVATIONS AND RESULTS 
In our study of 50 patients were selected and 50 control where 
selected to analyzed for the following 
• To determine the PREVALANCE OF ELEVATED HsCRP  
PATIENTS WITH ACUTE VASCULAR EVENTS  
• To compare with 50 controls of non vascular acute event. 
• To determine role of  HsCRP in determining the morbidity 
and mortality. 
• To study the prognostic implication. 
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ACCORDING TO VARIOUS REFERENCES QUOTED 
ABOVE THE LEVEL OF HsCRP determines prognosis as well as 
mortality. 
When we divide and analyze as follows 
1. With risk factors and elevated HsCRP. 
2. Without risk factors only elevated HsCRP. 
3. Control 
 
 
OBSERVATIONS ARE AS FOLLOWS 
TABLE – 1 
 
BASELINE CHARACTERS   
 
 
 
Sl.No Baseline Features Cases Control 
44 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
TABLE – 2 
 
CONTROLS 
 
 
 
 
1. Male 34 25 
2. Female 16 25 
3. Hindu 43 40 
4. Muslim 2 4 
5. Christian 5 6 
6. Family History  18 0 
7. Hypertension 29 0 
8. Diabetes Mellitus 26 0 
9. LDL >100 25 0 
10. HDL <50 for Female
         <40 for Male 
20 0 
11. TGL 20 0 
12. FBS 26 0 
13. ECHO 7 0 
14. Death 5 1 
No. of Diseases 
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TABLE – 3 
 
SEX WISE DISTRIBUTION   
 
 
Patients  
14 Fever 
4 LRI 
10 Trauma 
3 Post operative 
8 DKA 
2 Acute abdomen 
1 Haemorrhagic stroke 
1 SLE 
3 UTI 
1 Dengue 
1 ARF 
1 Myocarditis 
GENDER N . of Patients 
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SEX DISTRIBUTION
34
16
MALE
FEMALE
 
 
 
 
 
 
TABLE – 4 
 
COMMUNITY WISE DISTRIBUTION   
 
 
MALE 34 
FEMALE 16 
COMMUNITY No. of Patients 
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COMMUNITY WISE DISTRIBUTION
43
2 5
HINDU MUSLIM CHRISTIAN
 
 
 
 
 
 
 
 
 
 
TABLE – 5 
 
HINDU 43 
MUSLIM 2 
CHRISTIAN 5 
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RISK FACTOR DISTRIBUTION   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total No. of Patients 50 
RISK FACTOR 
HYPERTENSION 29 
DIABETES MELLITUS 26 
LDL >100 25 
HDL <50 for Female 
<40 for Male 
20 
TGL >150 20 
WITHOUT RISK 
FACTOR 
15 
49 
 
 
50 
 
TABLE – 6 
 
AVERAGE ELEVATED CRP  
 
 
Normal  Cases Cases with risk 
factor 
Cases without 
risk factor 
Controls 
<0.3 2.59 1.81 2.91 1.66 
 
 
 
2.59
1.81
2.91
1.66
0
0.5
1
1.5
2
2.5
3
Cases Cases with
risk factor
Cases
without risk
factor
Controls
AVERAGE ELEVATED CRP 
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TABLE – 7 
 
CLASS WISE DISTRIBUTION WITHOUT RISK FACTORS 
 
 
TYPE OF 
DISEASE 
LOW INTERMITTANT HIGH 
MYOCARDIAL 
INFARCTION 
0 2 0 
UNSTABLE 
ANGINA 
4 6 0 
STROKE 2 1 0 
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TABLE –8 
 
CLASS WISE DISTRIBUTION FOR ALL CASES 
 
 
TYPE OF 
DISEASE 
LOW INTERMITTANT HIGH TOTAL
MYOCARDIAL 
INFARCTION 
1 14 2 17 
UNSTABLE 
ANGINA 
5 13 0 18 
STROKE 9 5 1 15 
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TABLE –9 
 
MORTALITY AND ASSOCIATED RISK FACTORS 
 
Type No. of patients 
DEATH 5 
ASSOCIATED RISK FACTORS 
    HYPERTENSION 
 
3 
    DIABETES MELLITUS 3 
    HYPERLIPIDEMIA 4 
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TABLE –10 
 
TOTAL MORTALITY  
 
 
 No. of patients 
DEATH 5 
LOW RISK 1 
INTERMITTANT RISK 3 
HIGH RISK 1 
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RESULTS 
In my study, I found that: 
  The prevalence of elevated Hs CRP in selected cases  
  >0.3mg/dL - 46/50  92% 
  Prevalence of elevated Hs CRP in control 
  >0.3mg/dL - 43/50  86% 
 In considering the statistical significance, we had used Chi-square 
test and the result was obtained as follows: 
Cases 46 4 
Control 43 7 
 
 So, on cumulating the results, I found that: 
The observed percentage of elevated Hs CRP in these patients    
(both Control and Cases) is = 89/100 = 0.89. 
The observed percentage of normal levels of Hs CRP in these 
patients (both Control and Cases) is = 11/100 = 0.11. 
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INDEX ELEVATED CRP 
LEVEL 
NORMAL CRP 
LEVEL 
No. of cases observed 46 4 
No. of cases expected 40.94 5.06 
No. of controls observed 43.00 7.00 
No. of controls expected 37.87 7.70 
 
According to Chi-square formula,  
X2 = Σ (observed – expected)2 / expected value 
Σ (46 – 40.94)2 / 40.94 + (43 – 37.87)2 / 37.87 + (4 – 5.06)2 / 5.06 +  
    (7.00 – 7.70)2 / 7.70  
=   25.6036   +  11.236  +  47.1969  +  4.9 
        40.94           5.06          37.87        7.7 
=   4.726 
Degree of freedom = 1 
According to the above results, the P.value is <0.05.  So, this 
signifies that HsCPR has a definitive role in the cardiovascular pathology. 
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While comparing for patients with risk factor and without risk 
factors, we have used chi-square test and the results are obtained as 
follows. 
 
 
INDEX NO. OF CASES NO. OF CONTROLS 
Mean observed in cases  
with risk factors 
32 3 
Expected mean in cases 
with risk factors 
29.44 2.4 
Mean observed in 
controls without risk 
factors 
14 1 
Expected mean in 
controls without risk 
factors 
11.88 0.8 
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According to Chi-square formula: 
X2 = Σ (observed – expected)2 / expected value 
  Σ (32 – 29.44)2 / 29.44 + (14 –11.88)2 / 11.88 + (3 – 2.4)2 /2.4 +  
    (1 – 0.8)2 / 0.8  
=   1.3706 
Degree of freedom = 1 
According to the above results, the P.value is >0.05.  So, this shows 
that there is no statistical difference between prevalence of elevated 
HsCRP in cases with and without risk factors.  
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DISCUSSION  
 
When evaluating any novel risk factor as a potential new screening 
tool, clinicians need to consider whether (1) there is a standardized and 
reproducible assay for the marker of interest; (2) there is a consistent series 
of prospective studies demonstrating that a given parameter predicts future 
risk; (3) the novel marker adds to the predictive value of lipid screening; 
and (4) there is evidence that the novel marker adds to global risk 
prediction scores, such as that in the Framingham heart study. 
In AFCAPS and TESCAPS study which shown the role of HsCRP 
in cardiovascular events, has failed to include women in equal number.  In 
Jupiter trial, one third of women was included with large sample size.  But 
all the three studies have failed to include minority ethnics.  
In our study, we have selected 16 females, one third of study 
population which was not done in most of the previous studies. Moreover, 
we had included 10% of minority ethnics in our study and the study shows 
there is no significant variation with community.  In our study there is no 
significant difference in morbidity and mortality between males and 
females.
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 AFCAPS WOSCOPS JUPITER 
SAMPLE SIZE 6605 6595 17802 
WOMEN 997 0 6801 
MINORITY 350 0 5118 
DURATION 5.2 4.9 1.9 
DIABETES 6 1 0 
LDL 150 192 108 
HDL 36-40 44 49 
TGL 158 164 118 
CRP ----- ------ >2 
INTERVENTION LOVAS 10-40mg PROVAS40mg ROSUVA20mg 
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In our study, we had found that 35 persons have underlying 
cardiovascular risk factors.  35% of patients have family history of 
cardiovascular events.  15 patients have no risk factors, but have elevated 
CRP.   
The average elevated level of CRP in cases with risk factors and 
without risk factors are significantly above level of controls we have 
selected. 
Regarding the distribution of cases without risk factors, sevens cases 
are with intermediate risk value i.e., CRP between1 and 3.  Six cases are 
with low risk value.   
Regarding the distribution of cases, thirty two cases are in 
intermediate risk value, fifteen cases are with low risk value and three 
patients are in high risk group. 
Regarding the total mortality, most of the patients who were died   
i.e. three in number belong to intermediate risk category, one person with 
low risk and one person with high risk.  
On comparing the mortality in patients with various risk factors, 
hyperlipidemia plays a major role i.e. nearly four of the five deaths.  
Hypertension and diabetes are second most leading comorbid condition. 
The study clearly shows HsCRP has a definite role in cardiovascular 
morbidity and mortality.  
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CONCLUSION 
In this study it is clearly shown that most of patient selected had:    
• Very high prevalence of elevated HsCRP patients with acute vascular 
events.  
• There is definite association of HsCRP in acute vascular events than 
other non vascular conditions.   
• The analysis  in patient without any specific cardiovascular risk 
factors shows definite relative correlations  
• Probably HsCRP may play a role in pathogenesis as mentioned in 
the literature above which needs further studies.  
• Level of HsCRP has a definite role in determining the mortality in 
patients with acute vascular events. 
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SCOPE FOR FUTURE STUDY 
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SCOPE FOR FUTURE STUDIES 
Although hsCRP is by far the best-characterized and most reliable 
inflammatory biomarker for clinical use, several other markers of 
inflammation have shown promise in terms of predicting vascular risk. 
These include cytokines such as interleukin-6, soluble forms of certain cell 
adhesion molecules such as intercellular adhesion molecule (sICAM-1), P-
selectin, or the mediator CD40 ligand, as well as markers of leukocyte 
activation such as myeloperoxidase.  
Other inflammatory markers associated with lipid oxidation such as 
lipoprotein-associated phospholipase A2 and pregnancy-associated plasma 
protein A have also shown promise. However, each of these biomarkers 
has analytical issues that need careful evaluation before routine clinical 
use. For example, some have too short a half-life for clinical diagnostic 
testing, whereas the ability of others to predict risk in settings of broad 
populations has proved marginal thus far.  
Nonetheless, several of these inflammatory biomarkers can shed 
critical pathophysiological light on the atherothrombotic process, 
particularly at the time of plaque rupture. For example, soluble CD40 
ligand (probably released from activated platelets) may provide insight 
into the efficacy of specific antithrombotic agents independently of CRP. 
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Similarly, myeloperoxidase may provide prognostic information in cases 
of acute ischemia over and above that associated with troponin or 
CRP.Thus, continued evaluation of other inflammatory biomarkers may 
well provide targets for or monitors of therapy, particularly in the setting 
of acute coronary ischemia 
DIRECT PLAQUE IMAGING  
In addition to the use of inflammatory markers such as hsCRP, 
strategies to detect vascular disease will likely take several forms. One 
approach eschews risk factor measurement, but identifies preclinical 
disease through the noninvasive detection of atherosclerotic plaque. Such 
an approach can never truly prevent disease, only lead to early detection. 
However, because many therapies can delay clinical expression of disease 
once existing lesions are diagnosed, this approach merits consideration. 
At this time, a number of studies have indicated that coronary 
calcification as detected by computed tomography (CT) can detect 
preclinical atherosclerosis. It remains highly controversial, however, as to 
whether this approach is cost-effective or has an acceptable false-negative 
rate. Enrollment in these studies may be biased by referral patterns or self-
selection by patients. Part of the difficulty with coronary calcification as a 
clinical surrogate is that CT imaging probably detects the plaques least 
likely to rupture and does not detect the noncalcified thin-capped lesions 
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that appear to cause most clinical events. Thus, although coronary calcium 
provides a noninvasive measure of atherosclerotic burden, patients with 
low calcium scores cannot be dismissed as being at low risk.  
Furthermore, the clinical determinants of calcification are largely 
unknown and may not reflect propensity to plaque rupture. Studies 
indicating that hsCRP elevation corresponds to an approximate doubling of 
risk of plaque rupture at all levels of coronary calcium have demonstrated 
the complexity of this approach.Although advocates of CT imaging have 
noted that sensitivity for the presence of angiographic coronary disease is 
comparable with that of noninvasive stress testing such as perfusion 
scintigraphy or dobutamine echocardiography, the specificity of CT 
imaging in this setting is low. 
Relative to simple blood-based biomarkers, imaging tests currently 
incur considerable expense and thus may be cost-ineffective. One study 
has shown that provision of calcium scores does not effectively motivate 
patients' adherence to risk reduction regimens.   In other cases, whole-body 
scans obtained for vascular screening have led to expensive and 
unnecessary work-ups and biopsies of incidental findings, often requiring 
repeat imaging at substantial radiation doses. Even when the costs of these 
false-positive findings are ignored, the quality-adjusted life-year cost 
estimates for CT screening have been found unfavorable.  Several other 
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modalities for the noninvasive assessment of atherosclerosis exist, ranging 
from those that are well documented and inexpensive (e.g., ankle-brachial 
index) to those that are exploratory (e.g., thermography and magnetic 
resonance scanning).  
Perhaps the best studied noninvasive approach is the ultrasonic 
measurement of carotid intimal medial thickness. This technique has 
proved to have strong predictive value in general population studies and 
minimal additional expense is required, because most centers already have 
the required sonographic tools in place. Whether any imaging technique 
will prove cost-effective as a screening tool is currently under study in the 
Multiethnic Study of Atherosclerosis (MESA) being funded by the 
National Heart, Lung, and Blood Institute. In the Rotterdam Heart Study, 
in which simultaneous measures of atherosclerotic burden were obtained, 
the ankle-brachial index performed as well as carotid intimal medial 
thickness (IMT) and x-ray evidence of abdominal aortic calcification, but 
can be performed at no cost at the bedside. 
Genetic Determinants of Atherothrombosis  
Venous thromboembolism has a major genetic component, and 
advances in genetic diagnosis (factor V Leiden and the G20210A 
prothrombin mutation), as well as pharmacogenetic management of 
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warfarin, have already been implemented in many clinical practices By 
contrast, although clinicians understand that myocardial infarction, stroke, 
and other forms of arterial disease also have a major heritable component, 
no genetic screening test for atherothrombosis has yet found a substantive 
role in routine clinical practice.  
Nonetheless, with heritability estimates approaching 50 percent in 
several studies, this situation may well change in the future and has 
stimulated intensive ongoing investigation. 
Deciphering the genetic underpinnings of atherothrombosis presents 
considerable challenges because of major gene environment interactions. 
Also, atherothrombosis represents a prototypic complex disease in which 
multiple small effects accumulate and have a substantial population 
attributable risk. Some genetic determinants of atherothrombotic 
cardiovascular disease are well established and have been replicated in 
multiple cohorts. Perhaps the best known of these is the relationship 
between polymorphism in the apolipoprotein E (apo E) gene that codes for 
three common isoforms (E2, E3, and E4), which in turn are associated with 
differential risks of coronary heart disease.  
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In a meta-analysis of 48 studies incorporating information from over 
15,000 affected patients and 33,000 controls, carriers of the apo E e4 allele 
had a 42 percent higher risk for coronary heart disease (OR, 1.42; 95 
percent CI, 1.26 to 1.61) compared with those with the more common e3/3 
genotype, whereas carriers of the e4 allele had no significant increase in 
risk.Polymorphisms in the arachidonate 5-lipooxygenase–activating 
protein gene and its related pathways, gene, offspring Study, when 
compared with those with no parental history of cardiovascular disease, 
men with at least one parent with premature atherothrombosis (onset 
younger than age 55 for fathers and younger than age 65 for mothers) had 
an age-adjusted odds ratio of 2.6 (95 percent CI, 1.7 to 4.1) whereas the 
similar odds ratio for women was 2.3 (95 percent CI, 1.2 to 3.1).  
These effects compare in magnitude with those of smoking, 
hypertension, and hyperlipidemia in the Framingham cohort itself. As 
noted subsequently, analysis of data from the Women's Health Study has 
also recently found that a parental history of myocardial infarction before 
age 60, along with knowledge of CRP levels, can reclassify large numbers 
of patients as being at higher or lower risk than would have been 
anticipated on the basis of traditional risk factors alone. 
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The ultimate promise of an improved genetic understanding of 
cardiovascular risk is the concept of “personalized medicine,” in which 
targeted interventions can get the right drug to the right patient at the right 
time.  
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ANNEXURE 
 
 
 
 PROFORMA 
 MASTER CHART 
 ETHICAL COMMITTEE  APPROVAL 
ORDER 
 ABBREVIATIONS 
  
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PROFORMA 
 
Name:      Age:  
Sex:       Education: 
Occupation:     Community: 
H/O cardiovascular events 
Comorbidities:   
Diabetes:     Hypertension:   
Congestive Heart Failure:  Hepatitis B/C:  
H/O Smoking:      Alcoholism:  
Family h/o cardiovascular events: 
Now admitted for:                         
EXAMINATION: 
   Height                           weight                                           BMI         
   Pulse                             BP (upper limb) 
   CVS                RS                    Abd                                       CNS 
INVESTIGATIONS:  
CBC:   Hb:   TC:   DC:  ESR:  PCV:        
PLTS: 
Renal Function Test:  sugar:  urea:  creatinine:         Na, K 
Liver function tests: 
CXR: if indicated 
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ECG 
ECHO 
CPK MB 
CT BRAIN  
FBS  
FLP 
HsCRP 
 
Final diagnosis 
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1 Anjan 44 M Hindu No Yes Yes No No No Yes Yes Not applicable Yes i.7 MI Yes II   
2 Elumalai 52 M Hindu No Yes Yes No No No Yes Yes Not applicable Yes 2.4   Yes II   
3 Alagesan 50 M Hindu No Yes Yes Yes Yes Yes Yes Yes Not applicable Yes 1.4   Yes II   
4 Thirumathi 45 F Hindu Yes Yes No No No No Yes Yes Not applicable Yes 1.3   Yes II   
5 Selvi 47 F Hindu No No No Yes Yes Yes Yes Yes Not applicable Normal 3   Yes II   
6 Thiruvatharia 46 M Hindu Yes Yes Yes No No No Yes Yes Not applicable Normal 4   Yes III   
7 Angel 39 F Christian Yes Yes No Yes No No Yes Yes Not applicable Normal 0.94   Yes I   
8 Eswar 41 M Hindu No No No No No No Yes Yes Not applicable Yes 1.3   Yes II   
9 Ebinezar 47 M Christian No No No No No No Yes Yes Not applicable Yes 1.4   Yes II   
10 Selvam 55 M Hindu No No Yes Yes No No Yes Yes Not applicable Normal 1.7   Yes II   
11 Senbagam 62 F Hindu No Yes Yes Yes Yes Yes Yes Yes Not applicable Normal 1.9   Yes II   
12 Rajalaxmi 59 F Hindu No Yes Yes Yes Yes Yes Yes Yes Not applicable Normal 4   Yes III   
13 Devi 41 F Hindu Yes No No Yes No No Yes Yes Not applicable Normal 3   Yes II   
14 Christoper 50 M Christian No Yes Yes Yes Yes Yes Yes Yes Not applicable Normal 3   Yes II   
15 Habeeb 41 M Muslim No Yes Yes No No No Yes Yes Not applicable Normal 1   Yes II   
16 Saravanan 47 M Hindu No Yes Yes No No No Yes Yes Not applicable Normal 1.5   Yes II   
17 Shanmugam 47 M Hindu Yes Yes Yes Yes Yes Yes Yes Yes Not applicable Normal 2 UNSTABLE 
ANGINA Yes II   
18 Anbu 54 M Hindu Yes Yes Yes Yes Yes Yes Yes Yes Not applicable Normal 1.5   Yes II   
19 Anburajan 47 M Hindu Yes Yes Yes Yes Yes Yes Yes Yes Not applicable Normal 3   Yes II   
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20 Mathil 50 F Hindu No No No No No No Yes No Not applicable Normal 1.11   Yes II   
21 Thulisai 41 F Hindu No No No No No No Yes No Not applicable Normal 1.5   Yes II   
22 Arijagam 59 F Hindu Yes Yes Yes Yes No No Yes Yes Not applicable Normal 2.9   Yes II   
23 Mani 62 M Hindu Yes Yes Yes Yes Yes Yes Yes Yes Not applicable Normal 2.7   Yes II   
24 shanmugam 39 M Hindu No No No No No No Yes No Not applicable Normal 1.5   Yes II   
25 Arunagiri 46 M Hindu No No No No No No Yes No Not applicable Normal 2.7   Yes II   
 
 
 
 
 
 
26 Aseem 71 M Muslim No No No No No No Yes No 
Not 
applicable Normal 2   Yes II   
27 Fakurudin 64 M Christian No No No No No No Yes No 
Not 
applicable Normal 3   Yes I   
28 John 63 M Christian No No No No No No Yes No 
Not 
applicable Normal 0.8   Yes I   
29 Moorthi 60 M Hindu No No No No No No Yes No 
Not 
applicable Yes 0.9   Yes I   
30 Balaji 47 M Hindu No No No No No No Yes No 
Not 
applicable Normal 0.03   No II   
31 Rajalaxmi 48 M Hindu No No No No No No Yes No 
Not 
applicable Normal 3   Yes I   
32 Natarajan 52 M Hindu Yes Yes Yes Yes Yes Yes Yes Yes 
Not 
applicable Normal 0.7   Yes I   
33 Nagaraj 51 M Hindu Yes Yes Yes Yes No No Yes Yes 
Not 
applicable Normal 0.02   No II   
34 Govind 41 M Hindu Yes Yes Yes Yes No No Yes Yes 
Not 
applicable Normal 1.2   Yes II   
35 Pichumani 35 M Hindu No Yes Yes Yes Yes Yes Yes Yes 
Not 
applicable Normal 2.4   Yes II   
36 Chellam 65 F Hindu No Yes No No No Yes Yes No Not Normal 3 STROKE Yes II   
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applicable 
37 Raji 55 F Hindu No Yes Yes No No Yes Yes Yes 
Not 
applicable Normal 4   Yes III   
38 Devi 60 F Hindu Yes No No Yes Yes Yes Yes No 
Not 
applicable Normal 3   Yes II   
39 Dhanalaxmi 61 F Hindu Yes Yes Yes Yes Yes Yes Yes Yes 
Not 
applicable Normal 2.5   Yes II   
40 Priya 49 F Hindu No Yes Yes No No No Yes Yes 
Not 
applicable Normal 2.6   Yes II   
41 Danapriya 67 F Hindu No No No No No No Yes No 
Not 
applicable Normal 1   Yes II   
42 Laxmi 81 F Hindu Yes Yes Yes Yes Yes Yes Yes Yes 
Not 
applicable Normal 0.67   Yes I   
43 Psuedamani 47 M Hindu Yes Yes Yes Yes Yes Yes Yes Yes 
Not 
applicable Normal 0.2   No I   
44 Kanna 52 M Hindu Yes Yes Yes Yes Yes No Yes Yes 
Not 
applicable Normal 0.9   Yes I   
45 Kandasamy 47 M Hindu No No No No No No Yes No 
Not 
applicable Normal 0.19   No I   
46 Kasirajan 63 M Hindu Yes Yes Yes No No No Yes Yes 
Not 
applicable Normal 0.79   Yes I   
47 Veerapan 58 M Hindu No No No No No No Yes No 
Not 
applicable Normal 0.2   No I   
48 kumar 51 M Hindu No No No Yes Yes Yes Yes No 
Not 
applicable Normal 0.19   No I   
49 Pichai 60 M Hindu No No No Yes Yes Yes Yes No 
Not 
applicable Normal 0.7   Yes I   
50 siva 71 M Hindu No Yes Yes Yes Yes Yes Yes Yes 
Not 
applicable Normal 0.8   Yes I   
                                        
                              1.745714286         
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 MASTER CHART 
Sl.No Name Age Sex Community diagnosis HsCRP 
1 Rani 30 F Hindu fever   
2 Selvi 25 F Hindu LRI 1.2 
3 Reeta 45 F Christian LRI 1.3 
4 Prema 28 F Hindu FEVER 0.4 
5 Kannamma 40 F Hindu TRAUMA 0.2 
6 Rajeswari 35 F Hindu POST OP 1.3 
7 Najma 28 F Muslim TRAUMA 1 
8 Thawamani 40 F Hindu DKA 1.4 
9 Nansi 35 F Christian TRAUMA 0.3 
10 Mala 28 F Hindu AC.ABDOMEN 2 
11 Usha 32 F Hindu DKA 1.2 
12 Sarooja 40 F Hindu HAEMORHAGIC STROKE 1.4 
13 Madhavi 29 F Hindu SLE 2.1 
14 Kanmani 31 F Hindu FEVER 1 
15 Mari 28 F Hindu FEVER 2 
16 Kanjana 48 F Hindu FEVER 0.24 
17 Muniyamman 50 F Hindu DKA 0.24 
18 Revathi 42 F Hindu LRI 0.9 
19 Amutha 50 F Hindu UTI 0.8 
20 Indira 30 F Hindu AC.ABDOMEN 1.6 
21 Rani 40 F Hindu DENGUE 1.4 
22 Priya 32 F Hindu ARF 1 
23 Rajeetha 40 F Muslim MYOACARDITIS 2 
24 Patima 35 F Muslim DKA 1.8 
25 Antony 40 M Christian FEVER 1 
26 Raja 42 M Hindu FEVER 0.9 
27 Rajendran 40 M Hindu TRAUMA 1.2 
28 Abdulla 35 M Muslim POST OP 1 
29 govindan 48 M Hindu TRAUMA 1.3 
30 Kumaran 32 M Hindu DKA 1.2 
31 Sekar 35 M Hindu TRAUMA 0.34 
32 Senthil 28 M Hindu LRI 0.2 
33 James 18 M Christian DKA 0.45 
34 Santhanam 22 M Hindu LRI 0.35 
35 Dharmaraj 30 M Hindu fever 0.6 
36 Manoharan 40 M Hindu fever 0.7 
37 Arockiam 38 M Christian UTI 0.8 
38 Munian 28 M Hindu UTI 1.6 
39 Mariappan 32 M Hindu DKA 1.25 
40 Vellu 30 M Hindu FEVER 1.3 
41 Amalraj 30 M Christian FEVER 0.4 
42 venkatesh 28 M Hindu TRAUMA 0.46 
43 Sridhar 40 M Hindu POST OP 0.34 
44 Ganesh 41 M Hindu TRAUMA 1.2 
45 Mayilswamy 23 M Hindu DKA 1.4 
46 Durai 26 M Hindu TRAUMA 1.8 
47 Mrugeasan 28 M Hindu fever 2 
48 Dhanam 41 F Hindu FEVER 2 
49 Velan 45 M Hindu FEVER 0.25 
50             
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ABBREVIATIONS 
 
 
HsCRP : High-sensitivity C-reactive protein 
IL  : Interleukin 
LDL  : Low-density lipoprotein 
PAI-1 : Plasminogen activator inhibitor-1 
sICAM-1 : Intercellular adhesion molecule-1 
SAA  : Serum amyloid A 
sCD40L  : Soluble CD40 ligand 
t-PA  : Tissue plasminogen activator 
ECG  : Electrocardiogram 
ECHO : Echocardiogram 
CPKMB : Creatinine  Posphokinase (Miocardiam) 
 
 
 
 
 
 
 
 
 
 
